Core Insights - Comprehensive Healthcare Systems Inc. (CHS) is integrating artificial intelligence (AI) capabilities into its technology platform to enhance performance and operational efficiencies [1][2] - The AI strategy aims to improve healthcare benefits administration by enabling smarter automation and better decision-making for clients [2][3] - CHS's Novus 360 platform currently supports over 1 million lives and processes more than 1.6 billion transactions annually, indicating its significant scale in the market [2] Company Overview - CHS is a vertically integrated software as a service (SaaS) company focused on digitizing healthcare through its Healthcare Benefits Administration solutions [4] - The Novus 360 platform is utilized for various aspects of healthcare benefits administration, catering to self-funded employers, providers, and labor unions [4] Strategic Initiatives - The integration of AI is part of CHS's broader strategic roadmap aimed at driving long-term growth and increasing market penetration in the U.S. healthcare benefits administration software market, valued at approximately $4-6 billion [3] - The company is positioning itself as a next-generation technology partner within the U.S. healthcare benefits ecosystem by advancing data-driven capabilities and intelligent automation [8]

Core Viewpoint - Comprehensive Healthcare Systems Inc. is extending its non-brokered private placement for an additional 30 days to accommodate its controlling shareholder's participation [1]. Group 1: Offering Details - The private placement was initially announced on January 8, 2026, and upsized on January 26, 2026, with a first tranche closed on February 10, 2026, issuing 7,000,000 units at $0.50 each, totaling gross proceeds of $3.5 million [1][9]. - The extension allows for an additional 4,038,462 units at a price of $0.52 per unit, which could generate up to $2.1 million in gross proceeds [9]. - Each unit consists of one common share and one-half of a warrant, with each whole warrant exercisable at $1.00 for three years post-closing [2]. Group 2: Company Overview - Comprehensive Healthcare Systems Inc. is a vertically integrated SaaS company focused on digitizing healthcare through its Healthcare Benefits Administration solutions [5]. - The company's Novus 360 Healthcare Welfare and Benefits Administration platform is utilized for various aspects of healthcare benefits administration, serving self-funded employers, providers, and labor unions [5]. Group 3: Regulatory and Compliance - Completion of the offering is subject to customary closing conditions, including necessary approvals from the TSX Venture Exchange [3]. - All issued securities will be subject to hold periods under applicable securities laws, and the company may pay finder fees in compliance with applicable laws [3].

Core Viewpoint - Comprehensive Healthcare Systems Inc. has successfully closed the first tranche of its non-brokered private placement, raising a total of $3,500,000 by issuing 7,000,000 units at a price of $0.50 per unit [1]. Group 1: Offering Details - Each unit consists of one common share and one-half of a warrant, with the full warrant allowing the purchase of one common share at an exercise price of $1.00 for three years post-closing [2]. - The company paid finder fees totaling $214,200 in cash and issued 428,400 finder warrants, which are also exercisable at $0.50 for three years [3]. Group 2: Insider Participation - An insider purchased 945,000 units, accounting for 13.5% of the units issued in this tranche, which translates to approximately 3.8% of the total issued and outstanding shares upon closing [4]. - Assuming the exercise of associated warrants, the insider's stake would increase to approximately 5.6% of the total issued and outstanding shares [4]. Group 3: Company Overview - Comprehensive Healthcare Systems Inc. is a vertically integrated SaaS company focused on digitizing healthcare through its Healthcare Benefits Administration solutions [5]. - The company's Novus 360 Healthcare Welfare and Benefits Administration platform is utilized by various clients, including self-funded employers, providers, and labor unions, for comprehensive healthcare benefits administration [5].

Core Viewpoint - Comprehensive Healthcare Systems Inc. is increasing its non-brokered private placement due to strong investor interest, raising the total offering size to 11,038,462 units for gross proceeds of up to $5,600,000 [1][2]. Group 1: Offering Details - The initial offering consisted of 7,000,000 units priced at $0.50 per unit, generating gross proceeds of $3,500,000 [1]. - An additional 4,038,462 units will be offered at a price of $0.52 per unit, potentially raising an extra $2,100,000 [1]. - Insider participation in the offering is anticipated to reach up to $2,200,000, subject to regulatory approvals [1]. Group 2: Company Overview - Comprehensive Healthcare Systems Inc. is a vertically integrated SaaS company focused on digitizing healthcare through its Healthcare Benefits Administration solutions [4]. - The company's Novus 360 Healthcare Welfare and Benefits Administration platform is utilized for various aspects of healthcare benefits administration, catering to self-funded employers, providers, and labor unions [4].

Group 1 - Comprehensive Healthcare Systems Inc. (CHS) announced a non-brokered private placement of up to 7,000,000 units at a price of $0.50 per unit, aiming for gross proceeds of up to $3,500,000 [1][2] - Each unit consists of one common share and one-half of a warrant, with whole warrants allowing the purchase of one common share at an exercise price of $1.00 for three years, subject to accelerated expiry conditions [2] - The proceeds from the offering will be utilized for general working capital [2] Group 2 - The company plans to conduct a securities for debt transaction to settle up to US$893,250 (approximately C$1,232,685) in liabilities through the issuance of up to 2,465,369 common shares at a price of $0.50 per share [3] - Completion of the offering and the settlement is subject to customary closing conditions, including necessary approvals from the TSX Venture Exchange [4] - All securities issued will be subject to hold periods under applicable securities laws, and the company may pay finder fees in compliance with applicable laws [4] Group 3 - Comprehensive Healthcare Systems Inc. is a vertically integrated SaaS company focused on digitizing healthcare with solutions for healthcare benefits administration [6] - The company's Novus 360 Healthcare Welfare and Benefits Administration platform is utilized by clients for various aspects of healthcare benefits administration [6]

Core Insights - Comprehensive Healthcare Systems Inc. (CHS) has signed a five-year contract with Amalgamated Employee Benefits Administrators and Amalgamated Life Insurance Company to deploy its advanced administration platform for pension and employee benefits operations [1][2][4] - The contract is expected to increase CHS's annual revenue by approximately 25% over its duration [2] - The Novus360 platform will unify various administrative functions, enhancing efficiency and participant experience in multi-employer and union-based health and pension plans [3][4] Company Overview - CHS is a vertically integrated software as a service (SaaS) company focused on healthcare benefits administration, providing high-volume transaction-capable systems [9] - The Novus360 platform is designed to streamline workflows, improve compliance tracking, and offer advanced analytics in a cloud-based environment [3][5] Strategic Importance - The partnership with Amalgamated is seen as a significant milestone for CHS, reinforcing its position as a trusted technology partner in the health and pension benefits administration sector [6][4] - Amalgamated selected CHS for its expertise and the flexibility of the Novus360 platform, which is expected to enhance service delivery for employer groups and participants [5]

The entrance to Chico's in New Orleans. (Photo by: Jeffrey Greenberg/Universal Images Group via ... [+] Getty Images)Universal Images Group via Getty Images In a deal valued at $1 billion priced at $7.60 per share, private equity firm Sycamore Partners just acquired special fashion retailer Chico’s FAS, including the flagship Chico’s brand along with White House Black Market and Soma intimates.The Chico’s brands will be merged under Sycamore’s recently formed Knitwell Group that includes the Ann Taylor and ...

FORT MYERS, Fla., Jan. 5, 2024 /PRNewswire/ -- Chico's FAS, Inc. ("Company" or "Chico's FAS,"NYSE: CHS) today announced the completion of its acquisition by Sycamore Partners, a private equity firm specializing in retail, consumer, and distribution-related investments, for $7.60 per share, in an all-cash transaction valued at approximately $1 billion. "Joining the Sycamore portfolio of leading retail brands marks an important milestone for Chico's FAS and continues our journey as a customer-led, product-obs ...

PART I [Financial Statements](index=4&type=section&id=ITEM%201.%20FINANCIAL%20STATEMENTS) This section presents the unaudited condensed consolidated financial statements, including income, balance sheets, cash flows, and notes, for the periods ended October 28, 2023, and October 29, 2022 [Condensed Consolidated Statements of Income](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Income) The income statements show a decrease in net sales and net income for the thirteen-week period, while the thirty-nine-week period saw a slight increase in net income despite lower sales Income Statement Highlights (Thirteen Weeks Ended) | Metric | Oct 28, 2023 (in thousands) | Oct 29, 2022 (in thousands) | | :--- | :--- | :--- | | Net Sales | $505,126 | $518,332 | | Gross Profit | $196,449 | $207,440 | | Income from Operations | $10,529 | $31,599 | | Net Income | $5,040 | $24,619 | | Diluted EPS | $0.04 | $0.20 | Income Statement Highlights (Thirty-Nine Weeks Ended) | Metric | Oct 28, 2023 (in thousands) | Oct 29, 2022 (in thousands) | | :--- | :--- | :--- | | Net Sales | $1,584,995 | $1,617,967 | | Gross Profit | $638,358 | $655,519 | | Income from Operations | $110,409 | $135,223 | | Net Income | $104,270 | $101,512 | | Diluted EPS | $0.85 | $0.82 | [Condensed Consolidated Balance Sheets](index=7&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) The balance sheets show a strong liquidity position with reduced long-term debt and increased shareholders' equity as of October 28, 2023 Balance Sheet Summary (as of October 28, 2023) | Account | Amount (in thousands) | | :--- | :--- | | **Assets** | | | Cash and cash equivalents | $101,944 | | Inventories | $342,721 | | Total Current Assets | $529,634 | | Total Assets | $1,264,715 | | **Liabilities & Equity** | | | Total Current Liabilities | $442,341 | | Long-term debt | $24,000 | | Total Liabilities | $842,120 | | Total Shareholders' Equity | $422,595 | [Condensed Consolidated Statements of Cash Flows](index=10&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Cash flow statements indicate a decrease in net cash from operating activities for the thirty-nine-week period, with significant cash used in financing activities Cash Flow Summary (Thirty-Nine Weeks Ended) | Activity | Oct 28, 2023 (in thousands) | Oct 29, 2022 (in thousands) | | :--- | :--- | :--- | | Net cash provided by operating activities | $35,518 | $83,631 | | Net cash used in investing activities | ($35,435) | ($41,728) | | Net cash used in financing activities | ($51,516) | ($39,282) | | Net (decrease) increase in cash | ($51,433) | $2,621 | [Notes to Condensed Consolidated Financial Statements](index=11&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) The notes provide details on significant accounting policies, including the pending merger agreement, debt facilities, and a new supplier finance program - On September 27, 2023, the Company entered into a Merger Agreement to be acquired by Daphne Parent LLC for **$7.60 per share** in cash. The transaction is expected to close by the end of the **first calendar quarter of 2024**[98](index=98&type=chunk)[100](index=100&type=chunk) - As of October 28, 2023, the company had **$24.0 million** in net borrowings outstanding under its Credit Agreement, with an available additional borrowing capacity of approximately **$265.1 million**[147](index=147&type=chunk) - The company initiated a supplier financing program in Q3 2023. As of October 28, 2023, the outstanding payment obligation under this program was **$2.2 million**[149](index=149&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&A)](index=23&type=section&id=ITEM%202.%20MANAGEMENT%27S%20DISCUSSION%20AND%20ANALYSIS%20OF%20FINANCIAL%20CONDITION%20AND%20RESULTS%20OF%20OPERATIONS) Management discusses the company's financial performance, strategic pillars, and solid financial condition, noting the withdrawal of the fiscal 2023 outlook due to the pending merger - The company's growth strategy is focused on **four pillars**: (1) customer led, (2) product obsessed, (3) digital first, and (4) operationally excellent[171](index=171&type=chunk) - Due to the pending acquisition by Sycamore Partners, the Company is not providing a financial outlook and has **withdrawn its previously issued outlook for fiscal 2023**[164](index=164&type=chunk) - The company ended the third quarter with **$126.6 million** in cash and marketable securities, total liquidity of **$361.7 million**, and **$24.0 million** in long-term debt[160](index=160&type=chunk) [Results of Operations](index=27&type=section&id=Results%20of%20Operations) Third-quarter net sales and gross margin decreased due to lower comparable sales and higher occupancy costs, with merger-related costs impacting profitability Net Sales by Brand (Thirteen Weeks Ended) | Brand | Q3 2023 (in millions) | % of Total Sales | | :--- | :--- | :--- | | Chico's | $252 | 49.9% | | WHBM | $148 | 29.2% | | Soma | $105 | 20.9% | | **Total** | **$505** | **100.0%** | Comparable Sales Growth (Thirteen Weeks Ended) | Brand | Q3 2023 vs Q3 2022 | | :--- | :--- | | Chico's | 0.0% | | WHBM | (6.7)% | | Soma | (3.1)% | | **Total Company** | **(2.7)%** | - Q3 Gross margin decreased by **110 basis points** to **38.9%**, primarily due to higher occupancy costs and deleverage on lower sales[190](index=190&type=chunk) - Q3 SG&A expenses increased as a percentage of sales to **35.4%** from **33.9%** in the prior year, driven by higher marketing and store operating expenses[177](index=177&type=chunk)[4](index=4&type=chunk) [Liquidity and Capital Resources](index=30&type=section&id=Liquidity%20and%20Capital%20Resources) The company maintains strong liquidity with reduced long-term debt, increased inventories for holiday sales, and a net closure of 13 stores year-to-date Key Balance Sheet and Cash Flow Items | Metric | Oct 28, 2023 (in millions) | Change from Prior Year Period | | :--- | :--- | :--- | | Cash and Marketable Securities | $126.6 | Decreased from $140.7 | | Long-Term Debt | $24.0 | Decreased from $69.0 | | Inventories | $342.7 | Increased 12.7% | | YTD Net Cash from Operations | $35.5 | Decreased from $83.6 | - Net cash used in financing activities for the YTD period was **$51.5 million**, reflecting **$19.8 million** in share repurchases and debt repayments[13](index=13&type=chunk) - The company closed a net of **13 underperforming locations** during the first thirty-nine weeks of 2023, ending the quarter with **1,256 boutiques**. It also operates **58 international franchise locations**[16](index=16&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=35&type=section&id=ITEM%203.%20QUANTITATIVE%20AND%20QUALITATIVE%20DISCLOSURES%20ABOUT%20MARKET%20RISK) The company's market risk remains consistent, primarily exposed to interest rate changes on its Credit Agreement and marketable securities portfolio - The company is exposed to interest rate risk through its Credit Agreement. A hypothetical **100 basis point increase** in interest rates would increase interest expense by about **$0.8 million** over the loan's remaining term[21](index=21&type=chunk) - The marketable securities portfolio as of October 28, 2023, consisted of **$22.2 million** of securities with maturities within one year and **$2.5 million** with maturities over one year, all classified as available-for-sale[21](index=21&type=chunk) [Controls and Procedures](index=35&type=section&id=ITEM%204.%20CONTROLS%20AND%20PROCEDURES) Management concluded that disclosure controls and procedures were effective, with no material changes to internal controls over financial reporting during the quarter - The CEO and CFO concluded that as of the end of the period, the company's disclosure controls and procedures were **effective** in providing reasonable assurance[22](index=22&type=chunk) - **No changes** in internal controls over financial reporting occurred during the quarter that have materially affected, or are reasonably likely to materially affect, internal control over financial reporting[23](index=23&type=chunk) PART II – OTHER INFORMATION [Legal Proceedings](index=36&type=section&id=ITEM%201.%20LEGAL%20PROCEEDINGS) The company is not currently involved in any material legal proceedings beyond those arising in the normal course of business - The company is **not party to any material legal proceedings** outside of the normal course of business[150](index=150&type=chunk)[24](index=24&type=chunk) [Risk Factors](index=37&type=section&id=ITEM%201A.%20RISK%20FACTORS) This section highlights material risks, primarily focusing on the potential impacts and uncertainties associated with the pending merger agreement - The pendency of the Merger exposes the business to risks such as **difficulty maintaining customer/partner relationships**, **retaining key personnel**, and **management distraction**[47](index=47&type=chunk) - There is a risk that the **Merger may not be completed** in the expected timeframe, or at all, which could **negatively impact the stock price** and result in **significant unbenefited costs**[48](index=48&type=chunk) - **Potential shareholder litigation** related to the pending Merger could **delay or prevent its closing** and lead to **significant costs**[28](index=28&type=chunk) [Issuer Purchases of Equity Securities](index=39&type=section&id=ITEM%202.%20UNREGISTERED%20SALES%20OF%20EQUITY%20SECURITIES%2C%20USE%20OF%20PROCEEDS%2C%20AND%20ISSUER%20PURCHASES%20OF%20EQUITY%20SECURITIES) The company repurchased shares for employee tax obligations and authorized a new $100 million share repurchase program, with the full amount remaining available - In June 2023, the Company authorized a new **$100 million share repurchase program**, cancelling the remaining **$35.4 million** from the prior program. As of October 28, 2023, **$100 million remains available**[201](index=201&type=chunk) Share Purchases (Three Months Ended Oct 28, 2023) | Period | Total Shares Purchased | Average Price Paid per Share | | :--- | :--- | :--- | | Jul 30 - Aug 26, 2023 | 100,420 | $5.37 | | Aug 27 - Sep 30, 2023 | 5,845 | $5.04 | | Oct 1 - Oct 28, 2023 | 14,697 | $7.49 | | **Total** | **120,962** | **$5.61** | [Other Information](index=40&type=section&id=ITEM%205.%20OTHER%20INFORMATION) No directors or officers adopted, modified, or terminated Rule 10b5-1 or non-Rule 10b5-1 trading arrangements during the third quarter of 2023 - **No directors or officers** adopted, modified, or terminated a **Rule 10b5-1 trading arrangement** during the third quarter of 2023[61](index=61&type=chunk) [Exhibits](index=41&type=section&id=ITEM%206.%20EXHIBITS) This section lists the exhibits filed with the Form 10-Q, including the Merger Agreement, employee stock plan amendments, and CEO/CFO certifications - Filed exhibits include the **Agreement and Plan of Merger** (Exhibit 2.1), an amendment to the **Employee Stock Purchase Plan** (Exhibit 10.1), and **CEO/CFO certifications** (Exhibits 31.1, 31.2, 32.1, 32.2)[57](index=57&type=chunk)

[PART I – Financial Information](index=3&type=section&id=PART%20I%20%E2%80%93%20Financial%20Information) [Item 1. Financial Statements](index=4&type=section&id=Item%201.%20Financial%20Statements) The company presents its unaudited condensed consolidated financial statements for the periods ended July 29, 2023 [Condensed Consolidated Statements of Income](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Income) Net income increased to $59.3 million for the quarter, driven by a significant non-cash tax benefit Condensed Consolidated Statements of Income (Thirteen and Twenty-Six Weeks Ended) | Indicator | Thirteen Weeks Ended July 29, 2023 | Thirteen Weeks Ended July 30, 2022 | Twenty-Six Weeks Ended July 29, 2023 | Twenty-Six Weeks Ended July 30, 2022 | | :--- | :--- | :--- | :--- | :--- | | **Net Sales** | $545,126 | $558,720 | $1,079,869 | $1,099,635 | | **Gross Margin** | $216,900 | $231,514 | $441,909 | $448,079 | | **Income from Operations** | $46,544 | $58,217 | $99,880 | $103,624 | | **Net Income** | $59,324 | $41,961 | $99,230 | $76,893 | | **Diluted EPS** | $0.49 | $0.34 | $0.81 | $0.62 | [Condensed Consolidated Balance Sheets](index=7&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) The balance sheet reflects a strong liquidity position, significantly reduced long-term debt, and increased shareholders' equity Key Balance Sheet Items (in thousands) | Account | July 29, 2023 (Unaudited) | January 28, 2023 (Audited) | July 30, 2022 (Unaudited) | | :--- | :--- | :--- | :--- | | **Cash and cash equivalents** | $129,015 | $153,377 | $157,233 | | **Inventories** | $300,151 | $276,840 | $338,761 | | **Total Current Assets** | $514,301 | $515,363 | $571,502 | | **Total Assets** | $1,235,946 | $1,187,841 | $1,232,513 | | **Long-term debt** | $24,000 | $49,000 | $99,000 | | **Total Liabilities** | $820,689 | $852,208 | $934,636 | | **Total Shareholders' Equity** | $415,257 | $335,633 | $297,877 | [Condensed Consolidated Statements of Cash Flows](index=10&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Operating cash flow decreased year-over-year due to inventory spending, while financing cash use increased from debt repayment Cash Flow Summary (Twenty-Six Weeks Ended, in thousands) | Activity | July 29, 2023 | July 30, 2022 | | :--- | :--- | :--- | | **Net cash provided by operating activities** | $42,629 | $75,999 | | **Net cash used in investing activities** | ($16,042) | ($25,486) | | **Net cash used in financing activities** | ($50,949) | ($8,385) | | **Net (decrease) increase in cash** | ($24,362) | $42,128 | | **Cash and Cash Equivalents, End of period** | $129,015 | $157,233 | [Notes to Condensed Consolidated Financial Statements](index=11&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) The notes detail revenue by brand, tax rate reconciliation, debt structure, and share repurchase program updates Revenue by Brand (Twenty-Six Weeks Ended July 29, 2023) | Brand | Revenue (in thousands) | % of Total | | :--- | :--- | :--- | | Chico's | $547,867 | 50.7% | | WHBM | $303,518 | 28.1% | | Soma | $228,484 | 21.2% | | **Total Net Sales** | **$1,079,869** | **100.0%** | - The effective tax rate for the 13 weeks ended July 29, 2023 was a **28.6% benefit**, primarily due to a **$25.6 million non-cash discrete benefit** from the reversal of a valuation allowance on deferred tax assets[38](index=38&type=chunk) - As of July 29, 2023, the company had **$24.0 million in net borrowings** outstanding under its Credit Agreement, with an additional borrowing capacity of approximately **$265.1 million**[31](index=31&type=chunk)[84](index=84&type=chunk) - In June 2023, the company authorized a new **$100 million share repurchase program**, with the full amount available for future repurchases as of July 29, 2023[68](index=68&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&A)](index=22&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses brand performance, market share gains, a strong balance sheet, and the financial outlook for fiscal 2023 [Executive Overview](index=22&type=section&id=Executive%20Overview) The company achieved market share gains across all brands and maintained a strong liquidity position despite a slight sales decline - Q2 total comparable sales **decreased 3.0% YoY** but **increased 16.5%** on a two-year stacked basis[89](index=89&type=chunk) - All three brands (Chico's, WHBM, and Soma) **gained market share** in their respective target demographics during the second quarter[89](index=89&type=chunk) - The company ended Q2 with **$150.7 million in cash and marketable securities**, total liquidity of **$385.8 million**, and long-term debt at **$24.0 million**[89](index=89&type=chunk) [Fiscal 2023 Third Quarter and Full-Year Outlook](index=23&type=section&id=Fiscal%202023%20Third%20Quarter%20and%20Full-Year%20Outlook) The company provides its financial outlook for Q3 and the full fiscal year 2023, expecting continued sales and margin performance Fiscal 2023 Third Quarter Outlook | Metric | Expected Range | | :--- | :--- | | Consolidated net sales | $505M - $525M | | Gross margin rate | 38.5% - 39.0% | | SG&A as % of sales | 35.1% - 35.6% | | Earnings per diluted share | $0.08 - $0.12 | Fiscal 2023 Full-Year Outlook | Metric | Expected Range | | :--- | :--- | | Consolidated net sales | $2,145M - $2,175M | | Gross margin rate | 38.5% - 38.8% | | SG&A as % of sales | 33.0% - 33.3% | | Earnings per diluted share | $0.87 - $0.95 | [Results of Operations](index=26&type=section&id=Results%20of%20Operations) Net sales decreased slightly for the quarter and half-year, while gross margin fell in Q2 but improved for the 26-week period Comparable Sales vs. Prior Year (Thirteen Weeks Ended) | Brand | Q2 2023 vs Q2 2022 | | :--- | :--- | | Chico's | (2.5)% | | WHBM | (5.7)% | | Soma | (0.5)% | | **Total Company** | **(3.0)%** | Comparable Sales vs. Prior Year (Twenty-Six Weeks Ended) | Brand | YTD 2023 vs YTD 2022 | | :--- | :--- | | Chico's | 1.1% | | WHBM | (6.9)% | | Soma | (1.5)% | | **Total Company** | **(1.8)%** | - Q2 gross margin **decreased to 39.8% from 41.4% YoY**, primarily due to higher occupancy costs and lower average unit retail[126](index=126&type=chunk) - YTD gross margin **improved slightly to 40.9% from 40.7% YoY**, driven by lower inbound freight costs and higher average unit retail[151](index=151&type=chunk) [Liquidity and Capital Resources](index=28&type=section&id=Liquidity%20and%20Capital%20Resources) The company maintained strong liquidity, significantly reduced long-term debt, and lowered inventory levels from the prior year - **Long-term debt was reduced to $24.0 million** at the end of Q2 2023, down from $99.0 million at the end of Q2 2022[133](index=133&type=chunk) - Inventories totaled **$300.2 million, an 11.4% decrease** from $338.8 million in the prior-year quarter, primarily due to lower in-transit inventories[134](index=134&type=chunk) - Net cash from operating activities for the first half of 2023 was **$42.6 million**, compared to $76.0 million in the same period last year[13](index=13&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=34&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company's market risk exposure, primarily from interest rate fluctuations, has not materially changed since year-end - The company is exposed to interest rate risk through its Credit Agreement; a **100 basis point increase** in market rates would increase interest expense by about **$0.9 million**[161](index=161&type=chunk) - The marketable securities portfolio as of July 29, 2023, consisted of **$21.7 million**, primarily in U.S. government agencies and corporate bonds[41](index=41&type=chunk)[161](index=161&type=chunk) [Controls and Procedures](index=34&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were effective, with no material changes to internal controls - The CEO and CFO concluded that the company's disclosure controls and procedures were **effective** as of July 29, 2023[33](index=33&type=chunk) - **No material changes** to internal control over financial reporting occurred during the quarter[162](index=162&type=chunk) [PART II – Other Information](index=35&type=section&id=PART%20II%20%E2%80%93%20Other%20Information) [Legal Proceedings](index=35&type=section&id=Item%201.%20Legal%20Proceedings) The company is not party to any material legal proceedings outside of the normal course of business - The company reports **no material legal proceedings** other than those arising in the normal course of business[50](index=50&type=chunk)[54](index=54&type=chunk) [Risk Factors](index=36&type=section&id=Item%201A.%20Risk%20Factors) There have been no material changes to the risk factors previously disclosed in the company's 2022 Annual Report - **No material changes** have been made to the risk factors disclosed in the 2022 Annual Report on Form 10-K[201](index=201&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=37&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company details its share repurchase activity, including the authorization of a new $100 million program in June 2023 - In June 2023, the Board authorized a new share repurchase program for up to **$100 million** and cancelled the prior program[133](index=133&type=chunk)[185](index=185&type=chunk) Share Repurchases (Thirteen Weeks Ended July 29, 2023) | Period | Total Shares Purchased | Average Price Paid per Share | | :--- | :--- | :--- | | Apr 30 - May 27, 2023 | 4,096 | $4.96 | | May 28 - Jul 1, 2023 | 30,700 | $5.28 | | Jul 2 - Jul 29, 2023 | — | — | [Other Information](index=38&type=section&id=Item%205.%20Other%20Information) No directors or officers adopted or terminated a Rule 10b5-1 trading arrangement during the reporting period - **No directors or officers** adopted or terminated a Rule 10b5-1 trading arrangement during the third quarter[34](index=34&type=chunk) [Exhibits](index=39&type=section&id=Item%206.%20Exhibits) This section lists exhibits filed with the Form 10-Q, including compensation plans and required officer certifications - Exhibits filed include compensation agreements, the Amended and Restated 2020 Omnibus Stock and Incentive Plan, and **Sarbanes-Oxley Act certifications** from the CEO and CFO[17](index=17&type=chunk) [Signatures](index=40&type=section&id=Signatures) The report is duly signed by the Chief Executive Officer and Chief Financial Officer on August 30, 2023 - The Form 10-Q was signed by **CEO Molly Langenstein and CFO David M. Oliver** on August 30, 2023[188](index=188&type=chunk)